Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroko Shibata

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
Communications Biology|March 3, 2026
Integrative structural insights into the IgG-FcRn interactions revealed by engineered FcRn-immobilized affinity chromatographyMasato Kiyoshi, Takuo Suzuki, Naruaki Inoue, et al.
Therapeutic Innovation & Regulatory Science|August 7, 2025
Temporal Trends in the Prescription of Biosimilars and the Status of Switching from Original Biologics to Biosimilars at Individual and Institutional Levels in JapanMinako Matsumoto, Ryosuke Kumazawa, Akiko Ishii-Watabe, et al.
Scientific Reports|October 2, 2023
Specific peptide conjugation to a therapeutic antibody leads to enhanced therapeutic potency and thermal stability by reduced Fc dynamicsMasato Kiyoshi, Makoto Nakakido, Abdur Rafique, et al.
Biomaterials|March 30, 2004
The targeting of anionized polyvinylpyrrolidone to the renal systemHiroshi Kodaira, Yasuo Tsutsumi, Yasuo Yoshioka, et al.
Biomaterials|September 22, 2009
The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNFHiroko Shibata, Yasuo Yoshioka, Yasuhiro Abe, et al.
Biochemical and Biophysical Research Communications|October 10, 2007
Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptideToshiki Sugita, Tomoaki Yoshikawa, Yohei Mukai, et al.
Cytokine|September 26, 2008
The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis modelsHiroko Shibata, Yasuo Yoshioka, Akiko Ohkawa, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 24, 2025
Development of tCAP(N3): Affinity Peptide-Aided, pH-Triggered Strategy for Site-Specific Native IgG ModificationHiroko Kawakami, Abdur Rafique, Shugo Tsuda, et al.
Journal of Pharmaceutical Sciences|February 27, 2026
Flow imaging for particle characterization and quantification in biologicals: A perspective from the Japanese Biopharmaceutical ConsortiumHiroko Shibata, Tim Menzen, Andrea Hawe, et al.
Journal of Biochemistry|April 24, 2009
Fast binding kinetics and conserved 3D structure underlie the antagonistic activity of mutant TNF: useful information for designing artificial proteo-antagonistsYohei Mukai, Teruya Nakamura, Yasuo Yoshioka, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
Communications Biology|March 3, 2026
Integrative structural insights into the IgG-FcRn interactions revealed by engineered FcRn-immobilized affinity chromatographyMasato Kiyoshi, Takuo Suzuki, Naruaki Inoue, et al.
Therapeutic Innovation & Regulatory Science|August 7, 2025
Temporal Trends in the Prescription of Biosimilars and the Status of Switching from Original Biologics to Biosimilars at Individual and Institutional Levels in JapanMinako Matsumoto, Ryosuke Kumazawa, Akiko Ishii-Watabe, et al.
Scientific Reports|October 2, 2023
Specific peptide conjugation to a therapeutic antibody leads to enhanced therapeutic potency and thermal stability by reduced Fc dynamicsMasato Kiyoshi, Makoto Nakakido, Abdur Rafique, et al.
Biomaterials|March 30, 2004
The targeting of anionized polyvinylpyrrolidone to the renal systemHiroshi Kodaira, Yasuo Tsutsumi, Yasuo Yoshioka, et al.
Biomaterials|September 22, 2009
The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNFHiroko Shibata, Yasuo Yoshioka, Yasuhiro Abe, et al.
Biochemical and Biophysical Research Communications|October 10, 2007
Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptideToshiki Sugita, Tomoaki Yoshikawa, Yohei Mukai, et al.
Cytokine|September 26, 2008
The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis modelsHiroko Shibata, Yasuo Yoshioka, Akiko Ohkawa, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 24, 2025
Development of tCAP(N3): Affinity Peptide-Aided, pH-Triggered Strategy for Site-Specific Native IgG ModificationHiroko Kawakami, Abdur Rafique, Shugo Tsuda, et al.
Journal of Pharmaceutical Sciences|February 27, 2026
Flow imaging for particle characterization and quantification in biologicals: A perspective from the Japanese Biopharmaceutical ConsortiumHiroko Shibata, Tim Menzen, Andrea Hawe, et al.
Journal of Biochemistry|April 24, 2009
Fast binding kinetics and conserved 3D structure underlie the antagonistic activity of mutant TNF: useful information for designing artificial proteo-antagonistsYohei Mukai, Teruya Nakamura, Yasuo Yoshioka, et al.
Pageof 9